Methods This study used study-level results and was exempt from institutional review board
approval at Georgetown University. The review followed the guidelines included in the …

PURPOSE The aim of this work is to update key recommendations of the ASCO guideline
adaptation of the Cancer Care Ontario guideline on the selection of optimal adjuvant …

The cost of cancer drugs continues to escalate with the rapid development and approval of
novel therapies, especially over the course of the last decade. In human epidermal growth …

Background and Objective Unresectable hepatocellular carcinoma (uHCC) is the main
histological subtype of liver cancer and causes a great disease burden in China. We aimed …

BACKGROUND The addition of adjuvant trastuzumab to chemotherapy has significantly
improved outcomes for people with human epidermal growth factor receptor 2 (HER2) …

Background Breast cancer (BC) is the most common cancer globally among women, with
2,261,419 new cases in 2020; systemic treatment may be neo-adjuvant, adjuvant, or both …

Aim To assess the cost-effectiveness of adjuvant pembrolizumab versus observation for
patients with resected stage IIB/IIC melanoma from a third-party payers' perspective in …

Objectives To systematically review and assess the quality of the economic evidence of
adjuvant trastuzumab usage in early breast cancer in Asian countries. Methods Literature …

Objectives This study constructed and applied procedures for the estimation of unrelated
future medical costs (UFMC) of women with breast cancer in Israel (as a case study) and …

BACKGROUND Trastuzumab has a large financial impact on the average cost of breast
cancer treatment. This study reassessed the cost-effectiveness of listing the drug on the …